Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03789318 · ClinicalTrials.gov registry record · Phase 2

Study in Subjects Undergoing Complete Abdominoplasty

A Phase 2 study of Post-surgical Pain, sponsored by Concentric Analgesics.

Completed
Registry status
Phase 2
Development phase
54
Enrollment target
1
Study location

NCT03789318: Completed Phase 2 study of Post-surgical Pain, sponsored by Concentric Analgesics.

NCT03789318 is a Phase 2 study of Post-surgical Pain that has completed, run by Concentric Analgesics. The registered enrollment target is 54 participants, below the 201-participant average among 7 other Post-surgical Pain trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03789318, a Phase 2 study of Post-surgical Pain, has completed, sponsored by Concentric Analgesics.

COMPLETED
Registry status
Phase 2
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

Phase 2, single center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 vs. placebo in subjects undergoing an elective C-ABD under general anesthesia supplemented with a bupivacaine hydrochloride (HCl)transverse abdominis plane (TAP) block.

Primary Outcome

Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 96 hours

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Hydromorphone
  • DRUG Bupivacaine Hydrochloride
  • DRUG Fentanyl
  • DRUG CA-008 5 mg

Study Locations (1)

California

  • Lotus Clinical Research, LLC - Pasadena

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2018-12-03
Est. Completion 2019-06-12
Phase Phase 2
Concentric Analgesics

7 total trials

What the finished NCT03789318 record still lists

NCT03789318 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 201-participant average among 7 other Post-surgical Pain trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Post-surgical Pain appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT03789318 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03789318 about?

NCT03789318 is a clinical study titled "Study in Subjects Undergoing Complete Abdominoplasty". Phase 2, single center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 vs. placebo in subjects undergoing an elective C-ABD under general anesthesia supplemented with a bupivacaine hydrochloride (HCl)transverse abdominis plane (TAP) block.

What is the current status of trial NCT03789318?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2018-12-03. Estimated completion is 2019-06-12.

What conditions does trial NCT03789318 study?

This clinical trial studies the following conditions: Post-surgical Pain.

What interventions are being tested in trial NCT03789318?

The interventions under investigation include: Placebo (DRUG), Hydromorphone (DRUG), Bupivacaine Hydrochloride (DRUG), Fentanyl (DRUG), CA-008 5 mg (DRUG).

Who is sponsoring clinical trial NCT03789318?

This trial is sponsored by Concentric Analgesics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03789318 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post-surgical Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03789318, the US trial registry maintained by the National Library of Medicine. NCT03789318 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.